Leucine-rich repeat kinase 2 for beginners: Six key questions

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 3, 2012, Pages

  Kett, Lauren R ^a   Dauer, William T ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; LEUCINE RICH REPEAT KINASE 2; LRRK2 PROTEIN, HUMAN; PARKIN; PROTEIN SERINE THREONINE KINASE; TAU PROTEIN; UBIQUITIN PROTEIN LIGASE;

ANIMAL; ARTICLE; CYTOSKELETON; DISEASE COURSE; DNA TRANSCRIPTION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC EPIDEMIOLOGY; GENETICS; HEREDITY; HUMAN; LEWY BODY; LINKAGE ANALYSIS; MICROTUBULE; MISSENSE MUTATION; MITOCHONDRION; PARKINSON DISEASE; PHYSIOLOGY; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN TRANSPORT; REVIEW; RISK FACTOR; RNA TRANSLATION;

ANIMALS; CYTOSKELETON; DISEASE PROGRESSION; GENETICS; HUMANS; MICROTUBULES; MUTATION, MISSENSE; PARKINSON DISEASE; PHYSIOLOGY; PROTEIN TRANSPORT; PROTEIN-SERINE-THREONINE KINASES; UBIQUITIN-PROTEIN LIGASES;

EID: 84886642469     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a009407     Document Type: Article

References (73)

1. Alegre-Abarrategui J, Christian H, Lufino MM, Mutihac R, Venda LL, AnsorgeO, Wade-Martins R. 2009. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet 18: 4022-4034.
2. Andres-Mateos E, Mejias R, Sasaki M, Li X, Lin BM, Biskup S, Zhang L, BanerjeeR, Thomas B, Yang L, et al. 2009. Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine). J Neurosci 29: 15846-15850.
3. Biskup S, Moore DJ, Celsi F, Higashi S, West AB, Andrabi SA, Kurkinen K, YuSW, Savitt JM, Waldvogel HJ, et al. 2006. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 60: 557-569.
4. Biskup S, Moore DJ, Rea A, Lorenz-Deperieux B, Coombes CE, Dawson VL, Dawson TM, West AB. 2007. Dynamic and redundant regulation of LRRK2 and LRRK1 expression. BMC Neurosci 8: 102.
5. Bridges D, Moorhead GB. 2005. 14-3-3 Proteins: A number of functions for a numbered protein. Sci STKE 2005: re10.
6. Carson C, Saleh M, Fung FW, Nicholson DW, Roskams AJ. 2005. Axonal dynactin p150Glued transports caspase-8 to drive retrograde olfactory receptor neuron apoptosis. J Neurosci 25: 6092-6104.
7. Cookson MR, Hardy J, Lewis PA. 2008. Genetic neuropathology of Parkinson's disease. Int J Clin Exp Pathol 1: 217-231.
8. Dachsel JC, Behrouz B, Yue M, Beevers JE, Melrose HL, Farrer MJ. 2010. A comparative study of Lrrk2 function in primary neuronal cultures. Parkinsonism Relat Disord 16: 650-655.
9. Deng J, Lewis PA, Greggio E, Sluch E, Beilina A, Cookson MR. 2008. Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci 105: 1499-1504.
10. Dzamko N, Deak M, Hentati F, Reith AD, Prescott AR, Alessi DR, Nichols RJ. 2010. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J 430: 405-413.
11. Farrer MJ, Stone JT, Lin CH, Dachsel JC, Hulihan MM, Haugarvoll K, Ross OA, Wu RM. 2007. Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Parkinsonism Relat Disord 13: 89-92.
12. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. 2002. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11. 2-q13. 1. Ann Neurol 51: 296-301.
13. Funayama M, Hasegawa K, Ohta E, Kawashima N, Komiyama M, Kowa H, TsujiS, Obata F. 2005. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 57: 918-921.
14. Funayama M, Li Y, Tomiyama H, Yoshino H, Imamichi Y, Yamamoto M, MurataM, Toda T, Mizuno Y, Hattori N. 2007. Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population. Neuroreport 18: 273-275.
15. Gaig C, Marti MJ, Ezquerra M, Cardozo A, Rey MJ, Tolosa E. 2009. G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. BMJ Case Reports doi: 10. 1136/bcr. 08. 2008. 0632.
16. Gandhi PN, Wang X, Zhu X, Chen SG, Wilson-Delfosse AL. 2008. The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J Neurosci Res 86: 1711-1720.
17. Giasson BI, Covy JP, Bonini NM, Hurtig HI, Farrer MJ, Trojanowski JQ, Van Deerlin VM. 2006. Biochemical and pathological characterization of Lrrk2. Ann Neurol 59: 315-322.
18. Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, Shaw K, Bhatia KP, Bonifati V, Quinn NP, et al. 2005. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365: 415-416.
19. Gillardon F. 2009. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-βisoforms and modulates microtubule stability-A point of convergence in parkinsonian neurodegeneration? J Neurochem 110: 1514-1522.
20. Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O'Neill E, Meitinger T, Kolch W, Prokisch H, Ueffing M. 2006. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 15: 223-232.
21. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, Thomas KJ, et al. 2006. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23: 329-341.
22. Greggio E, Zambrano I, Kaganovich A, Beilina A, Taymans JM, Daniels V, LewisP, Jain S, Ding J, Syed A, et al. 2008. The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem 283: 16906-16914.
23. Guo L, Gandhi PN, Wang W, Petersen RB, Wilson-Delfosse AL, Chen SG. 2007. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res 313: 3658-3670.
24. Hatano T, Kubo S, Imai S, Maeda M, Ishikawa K, Mizuno Y, Hattori N. 2007. Leucine-rich repeat kinase 2 associates with lipid rafts. Hum Mol Genet 16: 678-690.
25. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, et al. 2008. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: A case-control study. Lancet Neurol 7: 583-590.
26. Herzig MC, Kolly C, Persohn E, Theil D, Schweizer T, Hafner T, Stemmelen C, Troxler TJ, Schmid P, Danner S, et al. 2011. LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet 20: 4209-4223.
27. Ho CC, Rideout HJ, Ribe E, Troy CM, Dauer WT. 2009. The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. J Neurosci 29: 1011-1016.
28. Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, Oota E, Lu B. 2008. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J 27: 2432-2443.
29. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, Alessi DR. 2007. LRRK2 phosphorylates moesin at threonine-558: Characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 405: 307-317.
30. Jorgensen ND, Peng Y, Ho CC, Rideout HJ, Petrey D, Liu P, Dauer WT. 2009. The WD40 domain is required for LRRK2 neurotoxicity. PLoS One 4: e8463.
31. Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, Gibson JM, RossOA, Lynch T, Wiley J, et al. 2005. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: Evidence of a common founder across European populations. Am J Hum Genet 76: 672-680.
32. Kanao T, Venderova K, Park DS, Unterman T, Lu B, Imai Y. 2010. Activation of FoxO by LRRK2 induces expression of proapoptotic proteins and alters survival of postmitotic dopaminergic neuron in Drosophila. Hum Mol Genet 19: 3747-3758.
33. Kumar A, Greggio E, Beilina A, Kaganovich A, Chan D, Taymans JM, Wolozin B, Cookson MR. 2010. The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS One 5: e8730.
34. Lee BD, Shin JH, VanKampen J, Petrucelli L, West AB, Ko HS, Lee YI, Maguire-Zeiss KA, Bowers WJ, Federoff HJ, et al. 2010a. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med 16: 998-1000.
35. Lee S, Liu HP, Lin WY, Guo H, Lu B. 2010b. LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction. J Neurosci 30: 16959-16969.
36. Lesage S, Durr A, Tazir M, Lohmann E, Leutenegger AL, Janin S, Pollak P, BriceA. 2006. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. New Engl J Med 354: 422-423.
37. Lewis PA, Greggio E, Beilina A, Jain S, Baker A, Cookson MR. 2007. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun 357: 668-671.
38. Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, Bogdanov M, Przedborski S, et al. 2009. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 12: 826-828.
39. Lin X, Parisiadou L, Gu XL, Wang L, Shim H, Sun L, Xie C, Long CX, Yang WJ, Ding J, et al. 2009. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant α-synuclein. Neuron 64: 807-827.
40. Lin CH, Tsai PI, Wu RM, Chien CT. 2010. LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ss. J Neurosci 30: 13138-13149.
41. MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich A. 2006. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52: 587-593.
42. Marras C, Schuele B, Munhoz RP, Rogaeva E, Langston JW, Kasten M, Meaney C, Klein C, Wadia PM, Lim SY, et al. 2011. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology 77: 325-333.
43. Nichols WC, Pankratz N, Hernandez D, Paisan-Ruiz C, Jain S, Halter CA, Michaels VE, Reed T, Rudolph A, Shults CW, et al. 2005. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 365: 410-412.
44. Nichols RJ, Dzamko N, Morrice NA, Campbell DG, Deak M, Ordureau A, Macartney T, Tong Y, Shen J, Prescott AR, et al. 2010. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J 430: 393-404.
45. Ohta E, Kawakami F, Kubo M, Obata F. 2011. LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: Impairment of the kinase activity by Parkinson's disease-associated mutations. FEBS Lett 585: 2165-2170.
46. Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, Hunt AL, Klein C, Henick B, Hailpern SM, et al. 2006. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. New Engl J Med 354: 424-425.
47. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N, et al. 2004. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44: 595-600.
48. Parisiadou L, Xie C, Cho HJ, Lin X, Gu XL, Long CX, Lobbestael E, Baekelandt V, Taymans JM, Sun L, et al. 2009. Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci 29: 13971-13980.
49. Ramonet D, Daher JP, Lin BM, Stafa K, Kim J, Banerjee R, Westerlund M, Pletnikova O, Glauser L, Yang L, et al. 2011. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One 6: e18568.
50. Ren G, Xin S, Li S, Zhong H, Lin S. 2011. Disruption of LRRK2 does not cause specific loss of dopaminergic neurons in zebrafish. PLoS One 6: e20630.
51. Ross OA, Toft M, Whittle AJ, Johnson JL, Papapetropoulos S, Mash DC, Litvan I, Gordon MF, Wszolek ZK, Farrer MJ, et al. 2006. Lrrk2 and Lewy body disease. Ann Neurol 59: 388-393.
52. Ross OA, Spanaki C, Griffith A, Lin CH, Kachergus J, Haugarvoll K, LatsoudisH, Plaitakis A, Ferreira JJ, Sampaio C, et al. 2009. Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. Parkinsonism Relat Disord 15: 466-467.
53. Sakaguchi-Nakashima A, Meir JY, Jin Y, Matsumoto K, Hisamoto N. 2007. LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins. Curr Biol 17: 592-598.
54. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe M, Takeda A, et al. 2009. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 41: 1303-1307.
55. Sheng D, Qu D, Kwok KH, Ng SS, Lim AY, Aw SS, Lee CW, Sung WK, Tan EK, Lufkin T, et al. 2010. Deletion of the WD40 domain of LRRK2 in zebrafish causes Parkinsonism-like loss of neurons and locomotive defect. PLoS Genet 6: e1000914.
56. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-RuizC, Lichtner P, Scholz SW, Hernandez DG, et al. 2009. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41: 1308-1312.
57. Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, West AB, Dawson VL, Dawson TM, Ross CA. 2005. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci 102: 18676-18681.
58. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. 2006. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9: 1231-1233.
59. Tan EK, Peng R, Wu YR, Wu RM, Wu-Chou YH, Tan LC, An XK, Chen CM, Fook-Chong S, Lu CS. 2009. LRRK2 G2385R modulates age at onset in Parkinson's disease: A multi-center pooled analysis. Am J Med Genet B 150B: 1022-10232.
60. Taylor JP, Mata IF, Farrer MJ. 2006. LRRK2: A common pathway for parkinsonism, pathogenesis and prevention? Trends Mol Med 12: 76-82.
61. Tong Y, Yamaguchi H, Giaime E, Boyle S, Kopan R, Kelleher R Jr., Shen J. 2010. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci 107: 9879-9884.
62. Tzivion G, Avruch J. 2002. 14-3-3 proteins: Active cofactors in cellular regulation by serine/threonine phosphorylation. J Biol Chem 277: 3061-3064.
63. Vitte J, Traver S, De Paula AM, Lesage S, Rovelli G, Corti O, Duyckaerts C, BriceA. 2010. Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease. J Neuropathol Exp Neurol 69: 959-972.
64. Wang D, Tang B, Zhao G, Pan Q, Xia K, Bodmer R, Zhang Z. 2008. Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons. Mol Neurodegener 3: 3.
65. Webber PJ, Smith AD, Sen S, Renfrow MB, Mobley JA, West AB. 2011. Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities. J Mol Biol 412: 94-110.
66. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM. 2005. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci 102: 16842-16847.
67. West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, Biskup S, Zhang Z, Lim KL, Dawson VL, et al. 2007. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16: 223-232.
68. Westerlund M, Belin AC, Anvret A, Bickford P, Olson L, Galter D. 2008. Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: Implications for Parkinson's disease. Neuroscience 152: 429-436.
69. Wszolek ZK, Pfeiffer B, Fulgham JR, Parisi JE, Thompson BM, Uitti RJ, Calne DB, Pfeiffer RF. 1995. Western Nebraska family (family D) with autosomal dominant parkinsonism. Neurology 45: 502-505.
70. Wszolek ZK, Vieregge P, Uitti RJ, Gasser T, Yasuhara O, McGeer P, Berry K, Calne DB, Vingerhoets FJG, Klein C, et al. 1997. German-Canadian family (Family A) with parkinsonism, amyotrophy, and dementia-Longitudinal observations. Parkinsonism Relat Disord 3: 125-139.
71. Wszolek ZK, Pfeiffer RF, Tsuboi Y, Uitti RJ, McComb AJ, Stoessl AJ, StrongoskyA, Zimprich B, Muller-Myhsok MJ, Farrer, et al. 2004. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 62: 1619-1622.
72. Xiong Y, Coombes CE, Kilaru A, Li X, Gitler AD, Bowers WJ, Dawson VL, Dawson TM, Moore DJ. 2010. GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet 6: e1000902.
73. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, et al. 2004. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44: 601-607.